Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
BTAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.17 - $13.36
Previous CloseN/A
Volume1.10M
Average Volume (3M)11.57M
Market Cap
$38.76M
Enterprise Value$84.71M
Total Cash (Recent Filing)$31.01M
Total Debt (Recent Filing)$105.88M
Price to Earnings (P/E)―
Beta2.64
Next Earnings
Nov 13, 2025EPS Estimate
-1.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.45
Shares Outstanding6,056,046
10 Day Avg. Volume34,089,673
30 Day Avg. Volume11,565,272
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.19
Enterprise Value/Revenue45.74
Enterprise Value/Gross Profit-399.57
Enterprise Value/Ebitda-3.04
Forecast
1Y Price Target
$5.00Price Target Upside-26.47% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe SERENITY trial receives a second favorable review from an independent Data Safety Monitoring Board, allowing the trial to continue without modification.
Regulatory ProgressBioXcel Therapeutics announced the submission of a pre-supplemental New Drug Application meeting package to the FDA for IGALMI™ in support of a potential label expansion for outpatient use.
Bears Say
Financial ConcernsCaution is advised in the near term given the company’s thinning cash position and rocky commercial uptake for Igalmi to date.
Market UptakePotential risks also involve slower-than-anticipated market uptake due to reimbursement issues or greater-than-expected levels of competition.
Bioxcel Therapeutics News
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $1.17 and its highest was $13.36 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Bioxcel Therapeutics Inc’s market cap is $38.76M.
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is Nov 13, 2025 which is in 92 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on Aug 12, 2025. The company reported -$2.45 earnings per share for the quarter, missing the consensus estimate of -$1.858 by -$0.592.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Overvalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -1.48.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 6,056,046 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$2.45 in its last earnings report, missing expectations of -$1.858. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Among the largest hedge funds holding Bioxcel Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics Inc’s shares valued at 0.
Bioxcel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (-26.47% Downside)
$5.00 (-26.47% Downside)
Blogger Sentiment
Bullish
BTAI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 24.4%
Last 30 Days ▲ 40.2%
Last 30 Days ▲ 40.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.28%
12-Months-Change
Fundamentals
Return on Equity
82.91%
Trailing 12-Months
Asset Growth
-53.15%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BTAI Stock 12 Month Forecast
Average Price Target
$5.00
▼(-26.47% Downside)
Technical Analysis
Traws Pharma
―
Relmada Therapeutics
―
Citius Pharmaceuticals
―
Hookipa Pharma
―
Athira Pharma
―
Ownership Overview
8.96% Insiders
1.28% Mutual Funds
2.74% Other Institutional Investors
86.72% Public Companies and
Individual Investors